NO914091L - Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase - Google Patents

Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase

Info

Publication number
NO914091L
NO914091L NO91914091A NO914091A NO914091L NO 914091 L NO914091 L NO 914091L NO 91914091 A NO91914091 A NO 91914091A NO 914091 A NO914091 A NO 914091A NO 914091 L NO914091 L NO 914091L
Authority
NO
Norway
Prior art keywords
hiv
reverstranscriptase
hydroxylated
inhibitors
procedure
Prior art date
Application number
NO91914091A
Other languages
English (en)
Other versions
NO914091D0 (no
Inventor
Shieh-Shung Tom Chen
Annjia Hsu
George A Doss
Mark E Goldman
Suresh K Balani
Anthony D Theoharides
Jr Jacob M Hoffman
Steven M Pitzenberger
Harri G Ramjit
Laura R Kauffman
Byron H Arison
Walfred S Saari
Clarence S Rooney
John S Wai
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO914091D0 publication Critical patent/NO914091D0/no
Publication of NO914091L publication Critical patent/NO914091L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nye forbindelser med formelen. Rj eller Reller begge er substituert minst én gang med OH; X er NR, 0, S,eller oksimido eller én til fem halogenatomer, C^-alkyltio, -alkyl-sulfinyl, -alkylsulfonyl, -alkoksy, -alkoksykarbonyl, cyan eller aryl; eller Rs og R, kan sammen danne en cykloalkylring med 5-7 ringatomer; eller Rj og Rkan sammen danne en cykloalkylring med 5-7 ringatomer; og Rog R, er H, C..-alkyl, C..-alkenyl, C..-cykloalkyl;. er aryl eller en. heterocyklisk rest som kan være substituert, med det forbehold at den heterocykliske rest ikke er ftalimid, eller farmasøytisk akseptabelt salt eller ester derav.Forbindelsene inhiberer HIV-reverstranskriptase og kan anvendes ved forhindring eller behandling av infeksjon med HIV og ved behandling av AIDS, eventuelt i kombinasjon med andre antivirusmidler, antiinfeksJonsmidler, immunomodulatorer, antibiotika eller vaksiner.
NO91914091A 1990-10-18 1991-10-17 Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase NO914091L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59996890A 1990-10-18 1990-10-18
US71232691A 1991-06-07 1991-06-07
US76958091A 1991-10-07 1991-10-07

Publications (2)

Publication Number Publication Date
NO914091D0 NO914091D0 (no) 1991-10-17
NO914091L true NO914091L (no) 1992-04-21

Family

ID=27416795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914091A NO914091L (no) 1990-10-18 1991-10-17 Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase

Country Status (10)

Country Link
EP (1) EP0481802A1 (no)
JP (1) JPH05170740A (no)
KR (1) KR920007998A (no)
AU (1) AU8596191A (no)
CA (1) CA2053512A1 (no)
IE (1) IE913647A1 (no)
IL (1) IL99731A0 (no)
MX (1) MX9101634A (no)
NO (1) NO914091L (no)
PT (1) PT99260A (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641769B2 (en) * 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
DE69315920T2 (de) * 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
US5604095A (en) * 1994-07-22 1997-02-18 Cancer Therapy & Research Center Unsymmetrically linked bisnaphthalimides as antitumor agents
US5561042A (en) * 1994-07-22 1996-10-01 Cancer Therapy And Research Center Diamine platinum naphthalimide complexes as antitumor agents
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
GB0212971D0 (en) * 2002-06-06 2002-07-17 Karobio Ab Novel compounds
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
ES2361338T3 (es) 2005-08-29 2011-06-16 Vertex Pharmaceuticals Incorporated Pirid-2-onas 3,5-disustituidas útiles como inhibidores de la familia tec de tirosina quinasas no ligadas a receptor.
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
MX2009000871A (es) * 2006-07-24 2009-05-08 Gilead Sciences Inc Novedosos inhibidores de transcriptasa inversa de vih.
RU2010125220A (ru) 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI3141542T1 (sl) 2011-12-28 2020-11-30 Global Blood Therapeutics, Inc. Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EA028529B1 (ru) 2014-02-07 2017-11-30 Глобал Блад Терапьютикс, Инк. Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
EP4257131A3 (en) 2014-09-19 2024-01-10 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
JPS5583786A (en) * 1978-12-20 1980-06-24 Dainippon Pharmaceut Co Ltd Diazepine derivative and its preparation
US4461901A (en) * 1983-03-04 1984-07-24 American Home Products Corporation Pyridyl containing 1,2-benzisothiazole-3-amine derivatives
EP0308977B1 (en) * 1987-09-25 1993-12-08 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Anthracycline derivatives having inhibitory activity against reverse transcriptase of human immunodeficiency virus
AU4074789A (en) * 1988-03-01 1989-09-22 Upjohn Company, The Coumarins to inhibit reverse transcriptase in humans
AU641769B2 (en) * 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase

Also Published As

Publication number Publication date
EP0481802A1 (en) 1992-04-22
CA2053512A1 (en) 1992-04-19
KR920007998A (ko) 1992-05-27
JPH05170740A (ja) 1993-07-09
IL99731A0 (en) 1992-08-18
AU8596191A (en) 1992-08-13
IE913647A1 (en) 1992-04-22
NO914091D0 (no) 1991-10-17
PT99260A (pt) 1992-09-30
MX9101634A (es) 1992-06-05

Similar Documents

Publication Publication Date Title
NO914091L (no) Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase
EA200400585A1 (ru) N-замещённые гидроксипиримидинон-карбоксамидные ингибиторы вич интегразы
YU53093A (sh) Benzoksazinoni kao inhibitori hiv reverzne transkriptaze
RU94027563A (ru) Соединения-ингибиторы вич протеазы, их использование для лечения спида, форикомпозиция
DK1441734T3 (da) Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
DE69228106D1 (de) HIV-Protease-Inhibitoren
ES2051641A1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
DK91690A (da) Anvendelse af adamantan-derivater til fremstilling af terapeutiske praeparater til behandling af ischaemi
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
NO953876D0 (no) HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS
SE8802790D0 (sv) Tripeptider med immunostimulerande och metastasforhindrande verkan
DE69430385D1 (de) Hiv-proteaseinhibitoren
CR20210664A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
FI911875A0 (fi) Kirala 2-(fosfonometoxi) propylguaniner som antivirala aemnen.
ATE122562T1 (de) Derivate von penciclovir zur behandlung von hepatitis-b-infektionen.
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
NO20002481L (no) Kombinasjonsterapi for behandling av AIDS
NO164352C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive, antivirale, substituerte isoksazolderivater.
PT79273A (en) 2-(n-pyrrolidino)-3-isobutoxy-n-substituted-phenyl-n-benzil-propylamines their preparation and pharmaceutical use
DK0774969T3 (da) HIV-proteaseinhibitor kombination
DK0728002T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 7-infektioner
ES2108254T3 (es) Composicion del inhibidor de infeccion con virus del sida.
DK0728001T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 6-infektioner